Revance Therapeutics to Release Third Quarter 2018 Financial Results on Thursday, November 1, 2018
October 18 2018 - 4:05PM
Business Wire
-Conference Call Scheduled for Thursday,
November 1, 2018 at 4:30pm ET-
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology
company developing neuromodulators for use in treating aesthetic
and therapeutic conditions, today announced that the Company will
release second quarter 2018 financial results on Thursday,
November 1, 2018 after the close of market. Revance will host
a corresponding conference call and a live webcast at 1:30pm
PT/4:30pm ET on the same day to discuss the results and
provide a business and pipeline update.
Individuals interested in listening to the conference call may
do so by dialing (855) 453-3827 for domestic callers, or (484)
756-4301 for international callers and reference conference ID:
2377607; or from the webcast link in the investor relations section
of the company's website at: www.revance.com.
A replay of the call will be available beginning November
1, 2018 at 4:30pm PT/7:30pm ET to November 2,
2018 at 4:30pm PT/7:30pm ET. To access the replay, dial
(855) 859-2056 or (404) 537-3406 and reference conference ID:
2377607. The webcast will be available in the investor relations
section on the company's website for 30 days following the
completion of the call.
About Revance Therapeutics, Inc.
Revance Therapeutics is an emerging Silicon Valley biotechnology
leader developing neuromodulators for the treatment of aesthetic
and therapeutic conditions. Revance uses a unique proprietary,
stabilizing excipient peptide technology to create novel,
differentiated therapies. The company’s lead compound,
DaxibotulinumtoxinA for Injection (RT002), is in clinical
development for a broad range of aesthetic and therapeutic
indications, including glabellar lines, cervical dystonia, plantar
fasciitis, upper limb spasticity and chronic migraine. RT002 has
the potential to be the first long-acting neuromodulator. The
company is advancing a robust pipeline of injectable and topical
formulations of daxibotulinumtoxinA. More information on Revance
may be found at www.revance.com.
“Revance Therapeutics” and the Revance logo are registered
trademarks of Revance Therapeutics, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181018005007/en/
INVESTORSRevance Therapeutics, Inc.:Jeanie Herbert,
714-325-3584jherbert@revance.comorBurns McClellan, Inc.:Ami
Bavishi, 212-213-0006abavishi@burnsmc.comorMEDIAGeneral
Media:TOGORUN:Mariann Caprino,
917-242-1087m.caprino@togorun.comorTrade Media:Nadine Tosk,
504-453-8344nadinepr@gmail.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Apr 2023 to Apr 2024
